Clinical Trial Update: An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) [Phase 1, Phase 2]

View source ↗

Summary

Open-label safety study of API 31510 topical cream for cutaneous squamous cell carcinoma in situ; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• API 31510 (API 31510)

Snippet

Sponsor: BPGbio | Conditions: Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-15